Munich Cluster for Systems Neurology
print


Breadcrumb Navigation


Content

Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181.

Ann Neurol. 2022 Mar 27. doi: 10.1002/ana.26360. Epub ahead of print. PMID: 35340050.

Authors/Editors: Oeckl P, Wagemann O, Halbgebauer S, Anderl-Straub S, Nuebling G, Prix C, Loosli SV, Wlasich E, Danek A, Steinacker P, Ludolph AC, Levin J, Otto M.
Publication Date: 2022

Abstract

This exploratory case–control study investigates the synaptic marker beta-synuclein in serum and plasma pTau181 in adults with Down syndrome (DS) with (sDS, n = 14) and without (aDS, n = 47) clinical symptoms of Alzheimer disease (AD) as well as euploid controls (n = 23). Beta-synuclein was higher in aDS and more pronounced in sDS (p < 0.0001), whereas pTau181 was only higher in sDS (p < 0.0001). Both markers showed good discriminatory power (area under the curve > 0.90) to distinguish symptomatic from asymptomatic AD. The data indicate that synaptic alterations belong to the earliest AD-associated events in DS and highlight the value of serum beta-synuclein as a potential early marker of AD. ANN NEUROL 2022

 

 04_oeckl

Related Links